A meta-analysis of randomized double-blind clinical trials in CMT1A to assess the change from baseline in CMTNS and ONLS scales after one year of treatment

CMT1A is the most common inherited peripheral neuropathy. There is currently no approved treatment. We performed a meta-analysis including four randomized, double-blind, Placebo-controlled clinical trials to assess the disease progression after one year under Placebo, Ascorbic Acid (AA) or PXT3003,...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Orphanet J Rare Dis
Autores principales: Mandel, Jonas, Bertrand, Viviane, Lehert, Philippe, Attarian, Shahram, Magy, Laurent, Micallef, Joëlle, Chumakov, Ilya, Scart-Grès, Catherine, Guedj, Mickael, Cohen, Daniel
Formato: Artigo
Lenguaje:Inglês
Publicado: BioMed Central 2015
Materias:
Letter to the Editor
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4482281/
https://ncbi.nlm.nih.gov/pubmed/26070802
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13023-015-0293-y
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares